News
Asarina Pharma AB (publ) Interim Report Q2 2019 released
2019-08-20 08:00
FINANCIAL HIGHLIGHTS 1 April – 30 June 2019 TOTAL OPERATING COSTS SEK 28.1M (11.5M) NET RESULT -25.8M (-9.7M) CASH AND CASH EQUIVALENTS (30 JUNE...
Last Patient In for landmark PMDD study
2019-08-15 08:00
“This is a crucial milestone. Full enrolment means we are on track to deliver top-line results in late March 2020 as promised. It also shows how...
Sepranolone receives FDA IND approval in menstrual migraine
2019-07-09 08:03
“The FDA IND approval in menstrual migraine is an important validation of the strong safety profile of our compound and also has very positive implications...
Asarina Pharma: Journal of Neuroendocrinology publishes preclinical data on effective Tourette syndrome therapy with no side effects
2019-06-12 08:00
The paper, Isoallopregnanolone reduces tic-like behaviors in the D1CT-7 mouse model of Tourette syndrome is co-authored by, amongst others, Marco Bortolato...
Premenstrual Dysphoric Disorder recognized in new WHO International Classification of Diseases ICD-11
2019-06-11 08:00
“The symptoms are severe enough to cause significant distress or impairment… and do not represent the exacerbation of a mental disorder&rdquo...
Asarina Pharma issues new shares to Ergomed plc
2019-06-03 22:17
The share issue has been triggered by the reaching of a planned milestone in the PMDD study, and it represents 1.5% of the current share capital in Asarina...
PMS & PMDD in spotlight at Gothenburg event for International Menstrual Hygiene Day
2019-05-23 08:38
The PMS & PMDD evening will take place at the University of Gothenburg, Sprängkullsgatan 19, 1700-1930. It has been organised by Isabel Lindström...
Asarina Pharma AB (publ) Interim Report, Q1 2019 released
2019-05-20 08:00
Financial Highlights The company maintained a strict management of its costs. The total cash position at the end of the Quarter was SEK 128.9 million...
Decisions from Annual General Meeting of Asarina Pharma, 8 May 2019
2019-05-08 16:20
Dividend In accordance with the board's proposal, the AGM resolved that no dividend is to be paid for the financial year 2018. Discharge from liability...
Decisions from Annual General Meeting of Asarina Pharma, 8 May 2019
2019-05-08 16:09
Dividend In accordance with the board's proposal, the AGM resolved that no dividend is to be paid for the financial year 2018. Discharge from liability...